Jeyun Jo

Jeyun Jo

Auto-generated profile, based on publicly available information

Jeyun Jo

Department of Pathology Stanford University School of Medicine Stanford United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JJJeyun Jo
Jeyun Jo
TUTulsi Upadhyay
Tulsi Upadhyay
EWEmily C. Woods
Emily C. Woods
KPKi Wan Park
Ki Wan Park
NPNichole J. Pedowitz
Nichole J. Pedowitz
MBMatthew Bogyo
Matthew Bogyo

27 February 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SWSijie Wang
Sijie Wang
EWEmily C. Woods
Emily C. Woods
JJJeyun Jo
Jeyun Jo
JZJiyun Zhu
Jiyun Zhu
AHAlthea Hansel-Harris
Althea Hansel-Harris
MBMatthew Bogyo
Matthew Bogyo

30 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TUTulsi Upadhyay
Tulsi Upadhyay
EWEmily C. Woods
Emily C. Woods
SAStephen Dela Ahator
Stephen Dela Ahator
KJKjersti Julin
Kjersti Julin
FFFranco F. Faucher
Franco F. Faucher
MBMatthew Bogyo
Matthew Bogyo
Staphylococcus aureus is a leading cause of bacteria-associated mortality worldwide. New tools are needed to both image and treat this pathogen. We previously identified a group of S. aureus serine hydrolases (Fphs), which regulate aspects of virulence and lipid metabolism. However, due to high structural and functional similarities, it remains challenging to distinguish the specific roles of members of this family. Here, we apply a high-throughput screening approach using a library of covalent electrophiles to identify inhibitors for FphB, FphE, and FphH. We identify selective covalent inhibitors for each target without the need for extensive medicinal chemistry optimization. Structural and biochemical analysis identify novel binding modes for several of the inhibitors. Functional studies using the inhibitors suggest that all three hydrolases likely play distinct functional roles in biofilm formation and virulence. This approach has the potential to be applied to target hydrolases in other diverse pathogens or higher eukaryotes.

22 March 2018 in Food & Function
Verified
Journal Article
Closed access
PDF file
JPJun Yeon Park
Jun Yeon Park
HYHwayoung Yun
Hwayoung Yun
JJJeyun Jo
Jeyun Jo
JBJI YUN BAEK
JI YUN BAEK
SLSang Cheon Lee
Sang Cheon Lee
Ki Sung  KangKi Sung Kang
Ki Sung Kang
In women, menopause refers to a series of physiological and mental symptoms of distress that result from a decrease in 17β-estradiol. In addition to the loss of fertility, the symptoms include facial flushing, depression, osteoporosis, sexual dysfunction, and genitourinary atrophy. Cirsium japonicum var. maackii is a perennial herbaceous species found in the mountains and fields of Korea, China, and Japan. The medicinal uses of C. japonicum include antioxidant, antidiabetic, antitumor, antifungal, and anti-inflammatory activities. We investigated the effect of C. japonicum extract in a rat model of menopause that exhibited rapid estrogen decline induced by ovariectomy (OVX rats). The rats were treated with C. japonicum extract for 10 weeks and the following parameters were measured: food intake, feed efficiency, body weight, total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, liver weight, 17β-estradiol, uterus weight, AST, ALT, bone mineral density (BMD), bone alkaline phosphatase, calcitonin, and osteocalcin. In OVX rats, the administration of 50 and 100 mg kg−1C. japonicum extract significantly decreased body weight, total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol and significantly increased 17β-estradiol and BMD. During the light/dark box test, the C. japonicum treatment group (100 mg kg−1) spent more time in the light chamber than in the dark area, which was reflective of their diurnal nature. Using a molecular docking simulation, we predicted the plausible binding mode of the active compounds of C. japonicum with the ligand binding domain of estrogen receptor (ER)-α and ER-β. These results showed that C. japonicum extract can treat the symptoms before and after the menopause.

1 December 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JJJeyun Jo
Jeyun Jo
HKHeegyu Kim
Heegyu Kim
JOJi Youn Oh
Ji Youn Oh
SKSoyeong Kim
Soyeong Kim
YPYeong Hye Park
Yeong Hye Park
HYHwayoung Yun
Hwayoung Yun

25 April 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
MKMin-Jung Kim
Min-Jung Kim
KJKwak Jinsook
Kwak Jinsook
HKHyung Seok Kim
Hyung Seok Kim
JHJihyung Han
Jihyung Han
JKJi An Kang
Ji An Kang
JJJee-Yeong Jeong
Jee-Yeong Jeong
We investigated the therapeutic potential and mechanisms of HR-19011, a novel eukaryotic translation initiation factor 2 subunit α (eIF2α) phosphorylation inducer, with a focus on its effects on the integrated stress response (ISR) pathway and cell-cycle regulation in K562 cells. Our findings revealed that HR-19011 exerts its anticancer effects primarily through the activation of heme-regulated inhibitor (HRI), leading to the phosphorylation of eIF2α, the induction of ISR signaling, and subsequent G1/S cell-cycle arrest. RNA sequencing analysis further highlighted significant changes in gene expression associated with the ISR pathway, particularly those involving the key components, activating transcription factor 4 and CHOP, underscoring the specific targeting of HRI by HR-19011. Additionally, HR-19011 suppressed the mTORC1 pathway, a critical regulator of cell growth and metabolism, through the downregulation of components such as phosphorylated S6K and phosphorylated 4EBP1, mediated by activating transcription factor 4 and CHOP. In vivo studies demonstrated that HR-19011 effectively inhibited tumor growth in a K562 xenograft model, without significant toxicity, and its broad efficacy across various hematologic malignancies further suggests its potential as a versatile anticancer agent. Our findings position HR-19011 as a promising candidate for targeting the HRI–eIF2α axis in cancer treatment, warranting further investigation and optimization for clinical application.